podcast with Tim Boreham
podcast with Tim Boreham
Melbourne, Oct 18, 2019 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".

Anatara Lifesciences: Standing out in the gut health market, solving scours in livestock and the future of antibiotics in the food chain

In the interview, Steve discusses:

- Anatara's journey to today and its dual opportunities in human and animal gut health

- The significant unmet need for complementary medicines in the treatment of irritable bowel syndrome and inflammatory bowel disease

- How Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement unique approach addresses all three significant factors in chronic bowel conditions - microbiome dysbiosis, inflammation and mucosal damage

- Recent successful completion of GaRP's preclinical program, with statistically significant efficacy data from its in vivo animal studies and further positive in vitro proof of concept data

- The upcoming human clinical trial for GaRP and in parallel, the preparation of a licencing package to approach potential partner companies in 2020

- The next step's for partnering the Company's anti-diarrhoeal product, Detach(r), in global markets and other livestock species

- Antimicrobial resistance is one of the greatest threats to mankind and how Detach(r) will help reduce in the use of antibiotics in livestock

Listen to the podcast interview please visit:
https://www.abnnewswire.net/lnk/HT7L087J


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    


Contact

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com


Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 58) (Last 30 Days: 461) (Since Published: 1077)